Condensed Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses
Research and development		$ 106,707	$ 82,070	$ 46,255
General and administrative		44,815	70,937	8,855
Total operating expenses		151,522	153,007	55,110
Operating loss		(151,522)	(153,007)	(55,110)
Interest income		22,083	5,983	2
Interest expense		(12)	215	0
Net loss before income taxes		(129,451)	(147,239)	(55,108)
Income tax expense (benefit)		5,996	896	38
Net and comprehensive loss before noncontrolling interest		(135,447)	(148,135)	(55,146)
Net loss and comprehensive loss attributable to noncontrolling interest		(99,979)	(40,103)	0
Net loss available to Class A ordinary shareholders		(35,468)		(55,146)
Common Class A [Member]
Operating expenses
Net loss available to Class A ordinary shareholders		$ (35,468)	$ (108,032)	$ (55,146)
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Basic	[1]	61,714,225	61,540,231
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Diluted	[1]	61,714,225	61,540,231
Net loss per ordinary share , Basic	[1]	$ (0.57)	$ (0.23)
Net loss per ordinary share , Diluted	[1]	$ (0.57)	$ (0.23)

[1] For the year ended December 31, 2022, net loss per Class A ordinary share and weighted average Class A ordinary shares outstanding reflects the period from July 11, 2022 through December 31, 2022, the period following the Business Combination, as defined in Note 1. For more information refer to Note 9.